Visit us at EHA
Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.
Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.